Conavi’s FDA-cleared Novasight heads for U.S. hospitals after emergency-like financing

Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) is approaching its first U.S. clinical placement of the next-generation Novasight Hybrid coronary imaging system with an unusually stark financing setup: the Canadian medtech company ended June with only C$0.9 million in cash before closing a C$10 million public offering in August to fund manufacturing transfer, initial inventory and hospital commercialization. Fiscal third-quarter net loss widened to C$6.3 million from C$3.6 million a year earlier, while quarterly licensing and research-service revenue was only about C$0.1 million. Against that financial backdrop, Novasight’s April FDA 510(k) clearance matters because the company now has a commercial product capable of changing its revenue profile rather than another pre-launch technology program consuming cash. The investment case has consequently become a race between operational execution and financing pressure: Conavi has enough new capital to start the U.S. launch, but a company valued at roughly C$23 million cannot afford a slow or expensive commercialization cycle indefinitely.

Novasight combines intravascular ultrasound and optical coherence tomography in one system, allowing physicians to obtain complementary information about coronary arteries through a simultaneous, co-registered workflow. Conavi is targeting initial U.S. hospital placement during the second half of 2026 and is completing production transfer, reliability work, inventory build and manufacturing documentation following the clearance.

Why combine IVUS and OCT in a single coronary imaging system?

Intravascular ultrasound and optical coherence tomography provide different but complementary information during coronary interventions. IVUS can image deeper into vessel structures and is useful for assessing vessel dimensions and plaque architecture, while OCT offers higher-resolution visualization of superficial structures, stent apposition and other fine anatomical details. Interventional cardiologists may use either modality depending on the lesion, clinical question and procedural workflow.

Conavi’s proposition is that physicians should not have to choose between the two. Novasight produces simultaneous and co-registered IVUS and OCT images through a single catheter-based workflow, potentially allowing the operator to move between deeper structural information and high-resolution surface detail without introducing separate imaging systems. The next-generation device is intended for intravascular imaging of coronary arteries in patients undergoing transluminal interventional procedures.

The clinical benefit still needs to prove itself commercially. Hospitals already use established IVUS and OCT systems supplied by much larger cardiovascular companies, so Conavi is not creating a market from scratch. Its challenge is demonstrating that having both modalities inside one workflow improves enough complex cases to justify new equipment, catheter purchasing and staff training.

What changed when the FDA cleared next-generation Novasight?

The FDA issued 510(k) clearance for the next-generation system in April, allowing Conavi to move from regulatory development into commercialization preparation. The product was reviewed as a Class II cardiovascular device through the traditional 510(k) pathway and includes software functions supporting image processing and segmentation.

Since then, Conavi has concentrated spending on transferring the product into production and preparing initial U.S. inventory. Management says the first American clinical placement remains targeted for the second half of 2026, making the remaining calendar year particularly important for a company that has generated little recurring revenue during the current fiscal period.

Ontario has provided some non-dilutive support. Conavi received a C$1.25 million Life Sciences Scale-Up Fund milestone after obtaining FDA clearance, taking total funding received under that program to C$1.75 million. The agreement can provide up to C$2.5 million if additional milestones are achieved, with proceeds intended to support manufacturing scale-up and commercialization.

How serious was Conavi’s cash position before the August financing?

The June balance sheet left little room for delay. Cash and cash equivalents were only C$0.9 million, down from C$5.8 million at the end of September 2025, while third-quarter operating expenses reached C$6.5 million. Research and development spending alone was C$4.4 million, up from C$3.2 million a year earlier as Conavi funded next-generation product work and the transition toward manufacturing.

Nine-month revenue fell to C$0.5 million from C$8.8 million because the prior-year comparison included milestone revenue under a technology-transfer and licensing agreement that did not recur. Nine-month net loss remained approximately C$13.8 million, almost unchanged from C$13.7 million a year earlier despite the sharp revenue decline. The numbers show why FDA clearance without financing would not have been enough to create a viable launch.

The C$10 million public offering closed on August 12 and is specifically intended to support U.S. system placement, early adoption and the foundation for broader commercialization. Relative to the C$0.9 million cash balance reported six weeks earlier, the gross proceeds amount to more than eleven times the company’s quarter-end liquidity.

That capital materially changes immediate solvency risk but does not eliminate the long-term funding question. Conavi’s fiscal third-quarter net loss of C$6.3 million equates to more than half the entire gross offering amount in only three months, although spending may change as development activities transition toward commercialization and the company begins generating product revenue.

Why is Conavi an unusually high-leverage medtech story?

At the August 28 close of C$0.16, Conavi carried a market capitalization of approximately C$23 million according to market data, while its 52-week trading range stood at C$0.145 to C$0.70. The stock was down about 16% over five trading days and more than 60% over the previous year, suggesting the market continues to assign considerable financing and execution risk despite FDA clearance.

For a company of that size, even a small number of successful U.S. placements could become financially visible, particularly if catheter utilization creates recurring consumable revenue after each system installation. The reverse is also true because a slow launch would leave Conavi carrying commercial personnel, manufacturing and support costs before revenue reaches meaningful scale.

This asymmetry makes the story different from a product launch by a diversified cardiovascular company. A multinational can absorb several quarters of disappointing adoption without changing its survival prospects. For Conavi, commercial traction can determine both valuation and how quickly the company needs to return to capital markets.

What will determine whether Novasight can win U.S. hospital placements?

Clinical differentiation is only the first hurdle. Conavi needs manufacturing reliability, catheter availability, responsive field support, physician training and a clear economic proposition for catheterization laboratories that already have established imaging relationships. Hospitals also need confidence that the smaller supplier can support equipment for years rather than simply win early technology evaluations.

Evidence generation could help. Conavi has highlighted peer-reviewed case reports demonstrating how hybrid IVUS-OCT information can assist lesion assessment, stent optimization and contrast management in complex coronary procedures, including patients with impaired renal function. Case reports can illustrate workflow advantages but do not substitute for larger comparative evidence demonstrating better clinical or economic outcomes.

The initial placement therefore matters more than its revenue contribution alone. It will test whether the transition from FDA clearance to manufacturing has worked, whether U.S. hospitals are willing to adopt the platform and whether physicians see enough value in simultaneous imaging to begin generating repeat catheter demand.

For investors, Conavi is now past the regulatory question that defined much of its earlier risk. The new question is harsher because it involves cash, manufacturing and customers at the same time. C$10 million gives management another window to execute, but with a C$6.3 million quarterly loss and a market value barely above twice the gross financing, that window needs to produce visible commercial evidence rather than another sequence of technical milestones.